Thromboembolic complications during cisplatin-containing chemotherapy for testicular cancer: A problem in the short and possibly also the long-term;Trombo-embolische complicaties tijdens cisplatinebevattende chemotherapie voor testiskanker: Een zorg voor de korte en wellicht ook voor de lange termijn

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 10, 2003, Pages 428-430

  Nuver, J ^a   Gietema, J A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN;

BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CANCER MORTALITY; DISEASE SEVERITY; HUMAN; MORBIDITY; PATHOGENESIS; SHORT SURVEY; TESTIS CANCER; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; HUMANS; MALE; RISK FACTORS; TESTICULAR NEOPLASMS; THROMBOEMBOLISM;

EID: 0037426013     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
2. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer. J Clin Oncol 2000;18:2169-78.
3. Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986;105:48-51.
4. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985;42:296-300.
5. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res 2000;99:503-9.
6. Shi Y, Inoue S, Shinozaki R, Fukue K, Kougo T. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn J Cancer Res 1998;89:757-67.
7. Dirix LY, Libura M, Libura J, Vermeulen PB, Bruijn EA de, Oosterom AT van. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs 1997;8:859-68.
8. Nuver J, Nieboer P, Gessel A van, Roon A van, Meer J van der, Smit AJ, et al. Acute vascular changes during cisplatin-containing chemotherapy in testicular cancer patients. Proceedings of the American Society of Clinical Oncology 2002;21:186a.
9. Brouha MEE, Bloemendal HJ, Kappelle LJ, Winter JB. Herseninfarct en myocardinfarct door cisplatinebevattende chemotherapie. Ned Tijdschr Geneeskd 2003;147:457-60.
10. Meinardi MT, Gietema JA, Veldhuisen DJ van, Graaf WT van der, Vries EG de, Sleijfer DT. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev 2000;26:429-47.
11. Meinardi MT, Gietema JA, Graaf WT van der, Veldhuisen DJ van, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-32.
12. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9.
13. Falanga A, Levine MN, Consonni R, Gritti G, Delaini F, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer. Thromb Haemost 1998;79:23-7.
14. Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med 1990;89:25-8.